252 related articles for article (PubMed ID: 23806460)
21. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies.
Abrahamsen TG; Sandersen H; Bustnes A
Pediatrics; 1996 Dec; 98(6 Pt 1):1127-31. PubMed ID: 8951264
[TBL] [Abstract][Full Text] [Related]
22. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.
Orange JS; Grossman WJ; Navickis RJ; Wilkes MM
Clin Immunol; 2010 Oct; 137(1):21-30. PubMed ID: 20675197
[TBL] [Abstract][Full Text] [Related]
23. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
25. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
Moore ML; Quinn JM
Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
[TBL] [Abstract][Full Text] [Related]
27. Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
Rosenbach K; Park M; Sanchirico M; Nwose O; Paris K
J Clin Immunol; 2023 Jul; 43(5):912-920. PubMed ID: 36809598
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.
Gardulf A
BioDrugs; 2007; 21(2):105-16. PubMed ID: 17402794
[TBL] [Abstract][Full Text] [Related]
29. Home self-administration of intravenous immunoglobulin therapy in children.
Kobayashi RH; Kobayashi AD; Lee N; Fischer S; Ochs HD
Pediatrics; 1990 May; 85(5):705-9. PubMed ID: 2109852
[TBL] [Abstract][Full Text] [Related]
30. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Li Z; Follman K; Freshwater E; Engler F; Yel L
J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
[TBL] [Abstract][Full Text] [Related]
31. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
Fasshauer M; Borte M; Bitzenhofer M; Pausch C; Pittrow D; Park M; Gladiator A; Jandus P
Adv Ther; 2023 Dec; 40(12):5168-5187. PubMed ID: 37751025
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous immunoglobulin replacement in primary immunodeficiencies.
Berger M
Clin Immunol; 2004 Jul; 112(1):1-7. PubMed ID: 15207776
[TBL] [Abstract][Full Text] [Related]
34. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up.
Galli E; Barbieri C; Cantani A; Solano A; Longhi MA; Businco L
Ann Allergy; 1990 Feb; 64(2 Pt 1):147-50. PubMed ID: 2106278
[TBL] [Abstract][Full Text] [Related]
35. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of patients with primary antibody deficiencies in Germany].
Borte M; Oertelt C; Högy B
Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
[TBL] [Abstract][Full Text] [Related]
38. Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG).
Knutsen AP; Leiva LE; Caruthers C; Rodrigues J; Sorensen RU
Clin Exp Immunol; 2015 Oct; 182(1):51-6. PubMed ID: 26230522
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.
Nicolay U; Kiessling P; Berger M; Gupta S; Yel L; Roifman CM; Gardulf A; Eichmann F; Haag S; Massion C; Ochs HD
J Clin Immunol; 2006 Jan; 26(1):65-72. PubMed ID: 16418804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
